VTRS

Viatris is a global, scaled generics-and-branded medicines platform where “moat” comes more from manufacturing, supply reliability, and portfolio breadth than from durable patents, which makes pricing pressure a structural headwind. The strategic pivot is to stabilize the base while layering in higher-value assets, highlighted by the first launch of Inpefa (sotagliflozin) in the UAE in January 2026 and a stated focus on advancing late-stage programs. Execution matters because the core portfolio remains exposed to erosion and competition typical of off-patent markets.

Financially, recent disclosure points to 2025 revenue of about $14.3B, adjusted EBITDA of $4.2B, adjusted EPS of $2.35, and free cash flow (excluding transaction costs) of about $2.2B, with 2026 guided to roughly ~2% revenue and adjusted EBITDA growth and $450–$550M of new-product revenue. Management also identified $650M of gross cost savings over three years (targeting $400M net by 2028), supporting cash generation and deleveraging capacity. Valuation looks cash-flow supported (often framed as a double-digit free-cash-flow yield), but the GAAP profile is noisy (recent negative EPS) and investor confidence hinges on translating adjustments into durable results.

Over the next 12 months, the bull case is “self-help plus pipeline”: cost actions, incremental launches, and clearer longer-term targets (3–4% revenue CAGR and 6–7% adjusted EPS CAGR in the 2026–2030 base case). Key risks are faster-than-expected price erosion in the base business, execution risk on restructuring/reinvestment, and any regulatory/commercial setbacks in the emerging innovative portfolio. I would watch 2026 quarterly cadence for evidence that growth is broad-based rather than purely cost-driven.

Recommendation: HOLD. The upside case is credible given strong free-cash-flow generation and a tangible cost-savings program, but the business mix still carries meaningful erosion risk and the gap between GAAP volatility and adjusted performance can limit multiple expansion.